NASDAQ:ARDX

Ardelyx Stock Forecast, Price & News

$7.28
-0.12 (-1.62 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.07
$7.41
50-Day Range
$6.55
$8.98
52-Week Range
$4.96
$9.23
Volume5.44 million shs
Average Volume1.62 million shs
Market Capitalization$718.60 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95
30 days | 90 days | 365 days | Advanced Chart
Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.


Ardelyx logo

About Ardelyx

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

352nd out of 2,097 stocks

Pharmaceutical Preparations Industry

162nd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

Is Ardelyx a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx
or view top-rated stocks.

What stocks does MarketBeat like better than Ardelyx?

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Ardelyx
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.33) by $0.01. The biopharmaceutical company earned $6.58 million during the quarter, compared to analysts' expectations of $1.10 million. Ardelyx had a negative trailing twelve-month return on equity of 78.63% and a negative net margin of 812.17%.
View Ardelyx's earnings history
.

How has Ardelyx's stock been impacted by Coronavirus?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARDX shares have increased by 21.7% and is now trading at $7.28.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARDX?

3 analysts have issued 12-month price targets for Ardelyx's shares. Their forecasts range from $14.00 to $14.00. On average, they expect Ardelyx's share price to reach $14.00 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts' price targets for Ardelyx
or view top-rated stocks among Wall Street analysts.

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:
  • Mr. Michael G. Raab, Pres, CEO & Director (Age 56, Pay $988k)
  • Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 57, Pay $596k)
  • Mr. David P. Rosenbaum, Chief Devel. Officer (Age 60, Pay $617.25k)
  • Mr. Justin A. Renz CPA, MST, M.S.T., MBA, CFO & Chief Accounting Officer (Age 49)
  • Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 58)
  • Ms. Kimia Keshtbod, Mang. of Corp. Communications & Investor Relations
  • Mr. Robert C. Blanks, Chief Regulatory Affairs & Quality Assurance Officer (Age 61)
  • Ms. Karen Harrigan, Sr. Director Market Devel.
  • Dan Pavicich, Sr. Director of Market Devel.
  • Ms. Susan Rodriguez, Chief Commercial Officer (Age 57)

Who are some of Ardelyx's key competitors?

What other stocks do shareholders of Ardelyx own?

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (6.16%), BlackRock Inc. (6.06%), Rock Springs Capital Management LP (5.24%), 683 Capital Management LLC (2.84%), Price T Rowe Associates Inc. MD (2.50%) and Thrivent Financial for Lutherans (2.47%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx
.

Which institutional investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Renaissance Technologies LLC, BNP Paribas Arbitrage SA, Morgan Stanley, Ikarian Capital LLC, RA Capital Management L.P., Silverarc Capital Management LLC, and State of Wisconsin Investment Board. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Michael Raab, Robert Blanks, and Susan Rodriguez.
View insider buying and selling activity for Ardelyx
or view top insider-selling stocks.

Which institutional investors are buying Ardelyx stock?

ARDX stock was purchased by a variety of institutional investors in the last quarter, including Kennedy Capital Management Inc., Prudential Financial Inc., 683 Capital Management LLC, Thrivent Financial for Lutherans, Dimensional Fund Advisors LP, Janus Henderson Group PLC, Citigroup Inc., and Letko Brosseau & Associates Inc..
View insider buying and selling activity for Ardelyx
or or view top insider-buying stocks.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $7.28.

How much money does Ardelyx make?

Ardelyx has a market capitalization of $718.60 million and generates $7.57 million in revenue each year. The biopharmaceutical company earns $-94,310,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Ardelyx have?

Ardelyx employs 129 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

Where are Ardelyx's headquarters?

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]


This page was last updated on 6/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.